

# Study Title:

# Quantitative suspension test for evaluation of virucidal activity in the medical area (Phase 2 Step1)

Microbiological Solutions Limited (MSL) Gollinrod, Walmersley, Bury, BL9 5NB, UK

Angela Davies, CEO

Customer: Zoono Uk & Europe Contact name: James Milnes

Email:

Address: Unit 15, Bunting Road, Bury St Edumnds, IP32 7BX


PO/Quote number: Q003496 Report date: 08/10/2020

Issue number: 1

Megan Barrett Laboratory Manager Peter Thistlethwaite Technical Projects Manager

The test results on this report refer only to the items tested as supplied by the customer. This report shall not be reproduced except in full and with written approval of Microbiological Solutions Ltd. All reports are archived for a minimum of 2 years.

The sample will be retained for 1 month unless otherwise requested in writing.



BS EN 14476:2013+A2:2019



#### Scope

The standard method BS EN 14476 describes a test method and the minimum requirements for virucidal activity of a chemical disinfectant and antiseptic products that form a homogenous physically stable preparation when diluted with hard water – or in the case of ready to use products that are not diluted when applied, - with water. Products can only be tested at a concentration of 80% (97% with a modified method for special cases) as some dilution is always produced by adding the test organisms and interfering substances. This European Standard applies to products that are used in the medical area in the fields of hygienic handrub, hygienic handwash, instrument disinfection by immersion, surface disinfection by wiping, spraying, flooding or other means and textile disinfection.


This European standard applies to areas and situations where disinfection is medically indicated. Such indication occurs in patient care, for example: In hospitals, in community medical facilities and in dental institutions or in clinics of schools, of kindergartens and of nursing homes, and may occur in the workplace and in the home. It may also include services such as laundries and kitchens supplying products directly for patients.

#### **Outline of Test Method (Obligatory Test Conditions)**

A sample of the test product is diluted in synthetic hard water in products diluted at point of use or water in the case of ready to use products is added to a test suspension of viruses in a solution of interfering substance. The mixture is maintained at one of the temperatures and contact times specified in the standard. At the end of this contact time, an aliquot is taken; the virucidal action in this portion is immediately suppressed by a validated method (dilutions of the sample in ice-cold cell maintenance medium). The dilutions are transferred into cell culture units either using monolayer or cell suspension. Infectivity tests are done either by plaque test or quantal tests. After incubation, the titres of infectivity are calculated according to Spearman and Käber or by plaque counting. Reduction of virus infectivity is calculated from differences of lg virus titres before (virus control) and after treatment with the product. The standard minimum spectrum of test organisms is Poliovirus, Adenovirus and Murine Norovirus.

#### **Acceptance Criteria**

The product when tested as above shall demonstrate at least a  $4 \log_{10}$  reduction against the test virus. The test is deemed valid where all control requirements are met.





	Test information	Deviation
Name of Product	Microbe Shield	
Batch Number & Expiry Date	Exp:05/2024 BN:365428	
Date of Delivery	04/08/2020	
Period of Analysis	04/09/2020-10/09/2020	
Manufacturer / Supplier	Zoono UK & Europe	
Storage Conditions	Ambient	
Appearance of the Product	Clear liquid	
Neutralisation Method	Dilution	
Product Diluent	Distilled water	
Test Concentrations	Neat (80%), Mid-range, Non active	
Experimental Conditions	Clean	
Interfering Substance	Clean 0.3g/l Bovine Albumin	
Test Temperature	20°C ± 1°C	
Temperature of Incubation	37°C ±1°C	
Identification of the Viral Strains:	Modified vaccinia virus Ankara (MVA), ATCC VR-1508	
Contact Times	5 minutes + 10s	
Stability and Appearance During Test	No Change Observed (Homogenous)	


#### **Deviations from Standard Method**

	There were no	deviations	from the	standard	method
--	---------------	------------	----------	----------	--------

## **Test Result Summary**

The test product received has achieved a 4-log reduction against Vaccinia virus when tested under the condition stipulated in this report.

See page 2 for acceptance criteria and raw data tables below for complete test results.





# Summary

Controls						
	MSL					
Conditions	SOLUTION PROVIDERS	Concentration	Contact time	log TCID50	log reduction	Control validation
Virus control (water)		N/A	5 minutes	7.04	N/A	Validated
Cytotoxicity (product)		Neat	N/A	2.50	N/A	Validated
<b>Product supression control</b>		Neat	Neat	7.00	0.04	Validated
Reference virus inactivation	n (formaldyehyde)	1.4%	5 minutes	4.83	2.21	Validated
Reference virus inactivation	n (formaldyehyde)	1.4%	15 minutes	3.96	3.08	Validated
Cytotoxicity (formaldehyde	e)	1.4%	N/A	2.50	N/A	Validated

Interference controls	SOLUTION PROVIDERS					
Condition		Concentration	Contact time	log TCID50	Log difference	Control validation
Interference control (untre	eated)	N/A	N/A	7.54	N/A	N/A
Interference control (treat	ted)	Neat	N/A	7.38	0.17	Validated

Test Results	SOLUTION PROVIDERS						
Condition		Concentration	Contact time	log TCID50	log reduction	Pass/Fail	
Test product		Neat	5 minutes	2.50	>4	Pass	
Test product		50%	5 minutes	3.50	3.54	Fail	
Test product		0.10%	5 minutes	6.96	0.08	Fail	



#### BS EN 14476:2013+A2:2019



## Raw data

Virus cont	trol (water)			Contact ti	me	5 minutes		
Dilution	Counts						% CPE	p(1-p)
-2	4	4	4	4	4	4	1	0
-3	4	4	4	4	4	4	1	0
-4	4	4	4	4	4	4	1	0
-5	4	4	4	4	4	4	1	0
-6	4	3	4	4	4	4	0.95833333	0.039931
-7	2	2	2	2	2	2	0.5	0.25
-8	1	1	0	0	0	0	0.08333333	0.076389
-9	0	0	0	0	0	0	0	0

Organism	Vacciniaviru	s
	ATTC VR-150	)8
d	1	
sum px	2.54	
n	8	
SD50	-7.04	
SE	0.23	
хр	-5	

Cytotoxici	ty (produc	t)		Product co	ncentratio	n	Neat	
Dilution	Counts						% CPE	p(1-p)
-2	4	4	4	4	4	4	1	0
-3	0	0	0	0	0	0	0	0
-4	0	0	0	0	0	0	0	0
-5	0	0	0	0	0	0	0	0
-6	0	0	0	0	0	0	0	0
-7	0	0	0	0	0	0	0	0
-8	0	0	0	0	0	0	0	0
0	0	0	0	0	0			
-9	0	0	0	0	0	0	0	0

Organism	Vacciniavirus	
	ATTC VR-1508	
d	1	
sum px	1.00	
n	8	
SD50	-2.50	
SE	0.00	
хр	-2	

Product su	pression c	ontrol		Product co	ncentratio	on	Neat	
Dilution	Counts						% CPE	p(1-p)
-2	4	4	4	4	4	4	1	0
-3	4	4	4	4	4	4	1	0
-4	4	4	4	4	4	4	1	0
-5	4	4	4	4	4	4	1	0
-6	4	4	4	4	4	4	1	0
-7	2	2	2	3	1	1	0.45833333	0.248264
-8	1	0	0	0	0	0	0.04166667	0.039931
-9	0	0	0	0	0	0	0	0

Organism	Vacciniavirus	
	ATTC VR-1508	
d	1	
sum px	1.50	
n	8	
SD50	-7.00	
SE	0.20	
хр	-6	

Interferen	ice control	(untreated	4)	Product co	ncentratio	on	Neat	
	Counts		-,					p(1-p)
-1	4	4	4	4	4	4	1	0
-2	4	4	4	4	4	4	1	0
-3	4	4	4	4	4	4	1	0
-4	4	4	4	4	4	4	1	0
-5	4	4	4	4	4	4	1	0
-6	4	4	4	4	4	4	1	0
-7	2	2	3	3	4	4	0.75	0.1875
-8	1	1	1	1	1	2	0.29166667	0.206597
-9	0	0	0	0	0	0	0	0
-10	0	0	0	0	0	0	0	0

Organism	Vacciniavirus	
	ATTC VR-1508	
d	1	
sum px	2.0417	
n	10	
SD50	<del>-7.542</del>	
SE	0.2093	
хр	-6	
•		

Microbiological Solutions Ltd

Gollinrod Walmersley Bury, BL9 5NB Tel: 0844 824 6003 Email: info@mls.io Web: www.msl.io Company number: 4218514



#### BS EN 14476:2013+A2:2019

## Raw data

Interferer	nce control	(treated)		Product co	oncentratio	Neat		
Dilution	Counts						% CPE	p(1-p)
-1	4	4	4	4	4	4	1	0
-2	4	4	4	4	4	4	1	0
-3	4	4	4	4	4	4	1	0
-4	4	4	4	4	4	4	1	0
-5	4	4	4	4	4	4	1	0
-6	4	4	4	4	4	4	1	0
-7	3	3	3	2	2	2	0.625	0.234375
-8	1	1	1	2	1	0	0.25	0.1875
-9	0	0	0	0	0	0	0	0
-10	0	0	0	0	0	0	0	0

Organism	Vacciniavirus	
	ATTC VR-1508	
d	1	
sum px	1.875	
n	10	
SD50	-7.375	
SE	0.2165	
хр	-6	

Reference	eference virus inactivation (formaldyehyde)					me	5 minutes	
Dilution	Counts						% CPE	p(1-p)
-2	4	4	4	4	4	4	1	0
-3	4	4	4	4	4	4	1	0
-4	3	3	3	4	4	4	0.875	0.109375
-5	2	2	2	1	1	1	0.375	0.234375
-6	1	1	0	0	0	0	0.08333333	0.076389
-7	0	0	0	0	0	0	0	0
-8	0	0	0	0	0	0	0	0
-9	0	0	0	0	0	0	0	0

Organism Vacciniavirus							
	ATTC VR-1508						
d	1						
sum px	2.33						
n	8						
SD50	-4.8 <mark>3</mark>						
SE	0.24						
хр	-3						

Reference	virus inac	tivation (fo	ormaldyeh	Contact tir	ne	15 minutes		
Dilution	Counts						% CPE	p(1-p)
-2	4	4	4	4	4	4	1	0
-3	4	4	4	4	3	3	0.91666667	0.076389
-4	2	2	2	3	1	1	0.45833333	0.248264
-5	1	1	0	0	0	0	0.08333333	0.076389
-6	0	0	0	0	0	0	0	0
-7	0	0	0	0	0	0	0	0
-8	0	0	0	0	0	0	0	0
-9	0	0	0	0	0	0	0	0

Organism	n Vacciniavirus				
	ATTC VR-1508				
d	1				
sum px	2.46				
n	8				
SD50	-3.96				
SE	0.24				
хр	-2				

Cytotoxici	tv (formal	dehvde)						
Dilution		,,					% CPE	p(1-p)
-2	4	4	4	4	4	4	1	0
-3	0	0	0	0	0	0	0	0
-4	0	0	0	0	0	0	0	0
-5	0	0	0	0	0	0	0	0
-6	0	0	0	0	0	0	0	0
-7	0	0	0	0	0	0	0	0
-8	0	0	0	0	0	0	0	0
-9	0	0	0	0	0	0	0	0

Vacciniavirus	
ATTC VR-1508	
1	
1.00	
8	
-2.50	
0.00	
-2	
	ATTC VR-1508  1  1.00  8  -2.50  0.00



#### BS EN 14476:2013+A2:2019

## Raw data

Test product Product concer			oncentratio	n	Neat	Contact time		5 minutes
Dilution	Counts						% CPE	p(1-p)
-2	4	4	4	4	4	4	1	0
-3	0	0	0	0	0	0	0	0
-4	0	0	0	0	0	0	0	0
-5	0	0	0	0	0	0	0	0
-6	0	0	0	0	0	0	0	0
-7	0	0	0	0	0	0	0	0
-8	0	0	0	0	0	0	0	0
-9	0	0	0	0	0	0	0	0

Organism	Vacciniavirus	
	ATTC VR-1508	
d	1	
sum px	1.00	
n	8	
SD50	-2.50	
SE	0.00	
хр	-2	

Test produ	est product Product concentration			50% Contact time			5 minutes	
Dilution	Counts						% CPE	p(1-p)
-2	4	4	4	4	4	4	1	0
-3	4	4	4	4	4	4	1	0
-4	0	0	0	0	0	0	0	0
-5	0	0	0	0	0	0	0	0
-6	0	0	0	0	0	0	0	0
-7	0	0	0	0	0	0	0	0
-8	0	0	0	0	0	0	0	0
-9	0	0	0	0	0	0	0	0

Organism	Vacciniavirus		
	ATTC VR-1508		
d	1		
sum px	1.00		
n	8		
SD50	-3.50		
SE	0.00		
	2		

Test prod	product Product concentration		0.10% Contact time		5 minutes			
Dilution	Counts						% CPE	p(1-p)
-2	4	4	4	4	4	4	1	0
-3	4	4	4	4	4	4	1	0
-4	4	4	4	4	4	4	1	0
-5	4	4	4	4	4	4	1	0
-6	4	4	4	4	4	4	1	0
-7	2	2	1	1	1	1	0.33333333	0.222222
-8	1	1	1	0	0	0	0.125	0.109375
-9	0	0	0	0	0	0	0	0

Organism	vacciniavirus		
	ATTC VR-150	08	
d	1		
sum px	1.46		
n	8		
CDEO	C 0C		

0.22



BS EN 14476:2013+A2:2019

#### **KEY**

CPE Cytopathic effect

Counts 0-4 indicating degree of cytopathic effect

0 = No effect, 1 = 25% CPE, 2 = 50% CPE, 3 = 75% CPE, 4 = 100% CPE

d Dilution factor (log)

Sum px Sum of % CPE from the highest dilution showing 100% CPE to the lowest dilution assessed.

n Number of dilutions

SD50 Dilution showing 50% of the end point according to Spearman-Kärber method

SE Standard error

xp Lowest dilution showing 100% CPE

TCID50 Titre causing 50% of the end point according to Spearman-Kärber

PASS = lg R greater than or equal to 4

FAIL = lg R less than 4

> greater than ≥ equal to or greater than < less than ≤ equal to or less than

#### Calculation notes

In cases where the highest dilution assessed has not shown 100% CPE, the value has been calculated assuming the dilution above this would give 100% CPE and the corresponding value has been assigned as <x.

The standard requires the product suppression control to show a <0.5 log reduction in viral titre. In cases where the product has failed to achieve the required 4 log reduction, but the product suppression control shows a >0.5 log reduction the result has been deemed as valid for fail as the consequence of inadequate suppression would be a partially extended contact time which would generate false positives, but not false negatives.

A similar approach has been taken in regards to the cytotoxicity controls. The standard requires a 4-log difference between the cytotoxicity level and the viral titre. In cases where this is not obtained, but the log reduction observed by the product is within the difference between the cytotoxicity levels and the viral titre the result is deemed acceptable for a fail as there will be no impact on the determination of efficacy.